NCT00258882View on ClinicalTrials.gov

Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine

CompletedOBSERVATIONAL
Enrollment

327,293

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2011

Study Completion Date

December 31, 2012

Conditions
Pertussis
Interventions
BIOLOGICAL

Tetanus Toxoid, acellular pertussis, diphtheria toxoid

0.5 mL, Intramuscular

Trial Locations (3)

Unknown

Oakland

Aurora

Portland

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00258882 - Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine | Biotech Hunter | Biotech Hunter